{"url_path":"/sec/trda/8-k/2026-05-19/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1689375/0001104659-26-063325-index.html","accession_number":"0001104659-26-063325","cik":"0001689375","ticker":"TRDA","issuer_name":"Entrada Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1689375/0001104659-26-063325-index.html","primary_entity_key":"0001689375","primary_entity_name":"Entrada Therapeutics, Inc."},"word_count":126,"has_tables":true,"body_markdown":"** **\n\n**Item 7.01 Regulation FD Disclosure.**\n\n \n\nOn May 18, 2026, Entrada Therapeutics, Inc. updated its corporate presentation\nfor use in meetings with investors, analysts and others. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to\nthis Current Report on Form 8-K (this “Current Report”) and is incorporated by reference herein.\n\n \n\nThe information in Item 7.01 of this Current Report, including the\naccompanying Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange\nAct or otherwise subject to the liability of such section, nor shall it be deemed incorporated by reference in any filing under the Securities\nAct or the Exchange Act, except as expressly set forth by specific reference in such filing."}